Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 83Breast Neoplasms 52Salivary Gland Neoplasms 3Prostate Adenocarcinoma 3Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Osteoporosis 2Neoplasm Metastasis 2Leiomyoma 2Breast Neoplasms, Male 2Advanced Breast Cancer 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Sarcopenia 1Radiation Injuries 1Primary Ovarian Insufficiency 1Primary Dysautonomias 1Patients With T1-4 Advanced Prostate Cancer 1Patient Compliance 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Myofibroma 1Lymphatic Metastasis 1Kidney Diseases 1Hypertension 1Hyperlipidemias 1Hot Flashes 1Hormone-sensitive Metastatic Breast Cancer 1

Interventions

bicalutamide 4pembrolizumab 1nilutamide 1exemestane 1darolutamide 1cabazitaxel 1apalutamide 1abemaciclib 1Vorinostat 1Tamoxifen 1Prophylactic Mastectomy 1Panobinostat 1Mifepristone 1Letrozole 1Histamine H2 Antagonists 1Histamine Antagonists 1Goserelin 1Dasatinib 1Aromatase Inhibitors 1Antiemetics 1Anastrozole 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bulbo-Spinal Atrophy, X-Linked × Goserelin × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡